Advertisement
Canada markets closed
  • S&P/TSX

    21,413.15
    +95.05 (+0.45%)
     
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • DOW

    39,131.53
    +62.43 (+0.16%)
     
  • CAD/USD

    0.7406
    -0.0013 (-0.17%)
     
  • CRUDE OIL

    76.57
    -2.04 (-2.60%)
     
  • Bitcoin CAD

    69,570.06
    -112.10 (-0.16%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,045.80
    +15.10 (+0.74%)
     
  • RUSSELL 2000

    2,016.69
    +2.85 (+0.14%)
     
  • 10-Yr Bond

    4.2600
    -0.0670 (-1.55%)
     
  • NASDAQ

    15,996.82
    -44.78 (-0.28%)
     
  • VOLATILITY

    13.75
    -0.79 (-5.43%)
     
  • FTSE

    7,706.28
    +21.79 (+0.28%)
     
  • NIKKEI 225

    39,098.68
    +836.48 (+2.19%)
     
  • CAD/EUR

    0.6841
    -0.0011 (-0.16%)
     

Stocks in play: PharmaTher Inc

Today submitted its meeting package with the U.S. Food and Drug Administration to discuss advancing KETARX™ into Phase 3 development as a treatment for levodopa-induced dyskinesia in Parkinson’s disease. This Type C meeting allows the Company to discuss with the FDA its plans for a Phase 3 clinical study to support the submission of a new drug application under the 505(b)(2) regulatory pathway for KETARX™ in treating LID-PD. In addition, the Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™. The Type C meeting is via written responses. The goal date for the FDA in providing its written responses is March 20, 2023. PharmaTher Inc shares C.PHRM are trading unchanged at $0.12.

Read: